Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

'Trump Account' newborns could have $1.9M by 28, Treasury Dept. says. Here's what's required to get that much

View original at finance.yahoo.com
'Trump Account' newborns could have $1.9M by 28, Treasury Dept. says. Here's what's required to get that much Shutterstock Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump accounts provide a more limited and restricted tax benefit than existing saving incentives, such as 529 accounts

    80% confidence
  • With no additional contributions beyond initial $1,000, accounts could turn into between $3,000 and $13,800 over 18 years depending on performance

    80% confidence
  • Annual costs of raising a small child average $29,419 today, a 35.7% increase from 2023 survey

    80% confidence
  • To reach $1.9 million by age 28, parents would need to max out accounts by investing maximum every year until child's 17th birthday, starting at $5,000 per year adjusted for inflation

    80% confidence
  • Trump accounts could grow to $1.9 million over 28 years

    80% confidence
  • Moby's individual stock picks have outperformed the S&P 500 index returns by an average of 11.95% per year over the last four years

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com